Chung Douglas C, Elford Alisha R, Jacquelot Nicolas
Department of Immunology, University of Toronto, Toronto, ON, Canada; Tumor immunotherapy program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Tumor immunotherapy program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Methods Cell Biol. 2025;192:1-15. doi: 10.1016/bs.mcb.2024.03.008. Epub 2024 Apr 24.
Breast cancer is the most common cancer in women and continues to have a significant impact in cancer-associated deaths worldwide. Investigating the complex roles of infiltrating immune subsets within the tumor microenvironment (TME) will enable a better understanding of disease progression and reveal novel therapeutic strategies for patients with breast cancer. The mammary-specific expression of polyomavirus middle T oncoprotein (MMTV-PyMT) was first established in 1992 by William Muller and is the most commonly used genetically engineered mouse model (GEMM) for breast cancer research. Innate lymphoid cells (ILCs) are composed of a diverse family of effector cells known to play important roles in defense against pathogens, tissue homeostasis, and tumor immunity. In mice, group 1 ILCs are composed of NK cells and ILC1s, which have been shown to have differential roles within the TME. Here, we provide a detailed methodology in characterizing tumor-infiltrating NK cells and ILC1s in MMTV-PyMT breast tumor model.
乳腺癌是女性中最常见的癌症，在全球癌症相关死亡中仍具有重大影响。研究肿瘤微环境（TME）中浸润性免疫亚群的复杂作用将有助于更好地理解疾病进展，并为乳腺癌患者揭示新的治疗策略。多瘤病毒中T癌蛋白的乳腺特异性表达（MMTV-PyMT）于1992年由威廉·穆勒首次建立，是乳腺癌研究中最常用的基因工程小鼠模型（GEMM）。固有淋巴细胞（ILC）由多种效应细胞组成，已知它们在抵御病原体、组织稳态和肿瘤免疫中发挥重要作用。在小鼠中，第1组ILC由NK细胞和ILC1组成，它们已被证明在TME中具有不同的作用。在这里，我们提供了一种详细的方法，用于在MMTV-PyMT乳腺肿瘤模型中表征肿瘤浸润性NK细胞和ILC1。
